GlassScriptPhysician profile
Yelena Birger
NPI 1376598136
$4,853.70
in general payments reported to CMS, 2019-2025
34 companies · $762 in 2025
The $762 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $653 · 2021: $981 · 2022: $532 · 2023: $489 · 2024: $701 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,951.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,184.37 | 2019-2025 | Ubrelvy, Linzess, Viberzi |
| Astrazeneca Pharmaceuticals LP | $749.04 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $459.70 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $248.32 | 2019-2022 | |
| Glaxosmithkline, LLC. | $240.89 | 2020-2024 | Trelegy Ellipta |
| Amgen INC. | $228.40 | 2020-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.49 | 2019-2024 | Jardiance, Tradjenta |
| Nestle Healthcare Nutrition INC. | $165.18 | 2020-2023 | |
| Lilly USA, LLC | $139.95 | 2019-2025 | Jardiance, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.74 | 2019-2024 | Xifaxan |
| Allergan, INC. | $132.04 | 2019 | |
| Phathom Pharmaceuticals, INC. | $114.49 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $101.13 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $101.09 | 2019-2024 | Linzess |
| Zimmer Biomet Holdings, INC. | $86.42 | 2023 | Comprehensive |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $78.09 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $63.60 | 2022-2024 | |
| Scilex Pharmaceuticals INC. | $55.77 | 2021-2024 | Ztlido |
| Biohaven Pharmaceutical Holding Company LTD. | $54.85 | 2022 | |
| Astellas Pharma US INC | $36.23 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $30.49 | 2025 | Zoryve |
| Pfizer INC. | $29.89 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $28.00 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $27.48 | 2021 | |
| Sanofi-Aventis U.S. LLC | $25.25 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $23.64 | 2020 | |
| Exact Sciences Corporation | $20.25 | 2025 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $19.21 | 2022 | |
| Viatris Specialty LLC | $14.12 | 2025 | Yupelri |
| Sumitomo Pharma America, INC. | $14.10 | 2025 | Gemtesa |
| Alfasigma USA, INC. | $12.65 | 2020 | |
| Mylan Specialty L.P. | $11.98 | 2020 | |
| Sanofi Pasteur INC. | $11.59 | 2019 | |
| Eisai INC. | $11.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yelena Birger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.